At the 2025 Global Forum on Nicotine in Warsaw, Emplicure Chief Clinical, Regulatory & Quality Officer Dr. Anna Franzén delivered a compelling presentation during the panel “Nicotine Pouches: What’s the Real Story?”.
What Dr. Franzén Shared
Dr. Franzén emphasised three critical pillars for nicotine pouches:
- Established safety of medicinal nicotine — highlighting how regulatory frameworks for nicotine replacement therapy offer a benchmark for non-combustible nicotine products.
- Public health opportunity — asserting that well-regulated nicotine pouches have real potential to reduce health harms at scale.
- Science-driven policy & innovation — insisting that clear evidence, robust safety data, and regulatory oversight must underpin harm reduction strategies.
These points reflect Emplicure’s commitment to ensure that product quality and consumer protection go hand in hand.
Why It Matters for GINN
- Clinical benchmarks — Positioning medicinal nicotine as the safety reference is a strong move toward alignment between health frameworks and novel nicotine products.
- Proportionate Regulation — The emphasis on science-based safety and innovation supports GINN’s advocacy for regulatory proportionality, especially regarding ingredients, purity, and labeling.
- Public Health Impact — Recognising the transformative potential of these products highlights the importance of credible leadership and robust evidence when engaging with regulators and public health bodies.
GINN’s Response
- Support for Quality Standards: We champion the adoption of clinical-grade benchmarks for product safety
- Promotion of Proportional Regulation: We advocate for policies that balance risk reduction and youth protection
- Collaboration for Innovation: We call on all stakeholders—manufacturers, scientists, and regulators—to share safety data and commit to transparent innovation
Final Word
Dr. Franzén’s insights at GFN25 underscore how science, safety, and regulation are converging—positioning nicotine pouches not just as commercial products, but as public health tools when guided by evidence. Her message aligns closely with GINN’s mission to promote harm reduction through integrity, innovation, and inclusivity.
